EVFM Stock Price, Evofem Biosciences Inc Quote, Chart

Market Summary

USD0.01-0.01

Market Closed

-50.00%

EVFM Stock Price

View Fullscreen

EVFM RSI Chart

EVFM Valuation

Market Cap

620.6K

Price/Earnings (Trailing)

0.01

Price/Sales (Trailing)

0.04

EV/EBITDA

0

Price/Free Cashflow

-0.16

EVFM Price/Sales (Trailing)

EVFM Profitability

EBT Margin

315.63%

Return on Equity

-71.5%

Return on Assets

614.87%

Free Cashflow Yield

-631.64%

EVFM Fundamentals

EVFM Revenue

Revenue (TTM)

16.0M

Rev. Growth (Yr)

-37.98%

Rev. Growth (Qtr)

-25.54%

EVFM Earnings

Earnings (TTM)

50.5M

Earnings Growth (Yr)

-104.29%

Earnings Growth (Qtr)

-127.48%

Breaking Down EVFM Revenue

Last 90 days

-66.7%

How does EVFM drawdown profile look like?

EVFM Financial Health

Current Ratio

0.09

EVFM Investor Care

Buy Backs (1Y)

83.49%

Diluted EPS (TTM)

-1.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.0M	0	0	0
2023	18.4M	14.8M	13.6M	18.2M
2022	11.4M	15.6M	20.2M	16.8M
2021	2.4M	4.3M	6.3M	8.2M
2020	0	0	0	446.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Evofem Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 31, 2022	file justin j.	back to issuer	-	-	-30,000	chief financial officer
Dec 31, 2022	pelletier saundra l	back to issuer	-	-	-50,000	chief executive officer
May 27, 2022	pelletier saundra l	bought	49,702	0.3525	141,000	chief executive officer
Feb 18, 2022	fitzpatrick alexander a	acquired	-	-	300,000	general counsel and secretary
Feb 18, 2022	pelletier saundra l	acquired	-	-	750,000	chief executive officer
Feb 18, 2022	file justin j.	acquired	-	-	450,000	chief financial officer
Dec 31, 2021	fitzpatrick alexander a	back to issuer	-	-	-120,000	general counsel and secretary
Dec 31, 2021	pelletier saundra l	back to issuer	-	-	-300,000	chief executive officer
Dec 31, 2021	file justin j.	back to issuer	-	-	-120,000	chief financial officer
Dec 20, 2021	pelletier saundra l	bought	50,625	0.375	135,000	chief executive officer

Are Funds Buying or Selling EVFM?

Are funds buying EVFM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EVFM

No. of Funds

Unveiling Evofem Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cvi investments, inc.	0.9%	102,799	SC 13G/A
Feb 14, 2023	cvi investments, inc.	5.5%	7,033,373	SC 13G/A
Jul 19, 2022	cox todd stewart	9.29%	3,919,866	SC 13G
Feb 14, 2022	cvi investments, inc.	5.8%	1e+07	SC 13G/A
Sep 10, 2021	morgan stanley	0.1%	196,829	SC 13G/A
Jul 12, 2021	blackrock inc.	2.3%	3,395,720	SC 13G/A
Jun 04, 2021	morgan stanley	5.1%	7,631,470	SC 13G
May 28, 2021	cvi investments, inc.	9.9%	15,567,602	SC 13G
May 20, 2021	invesco ltd.	-	591,960	SC 13D/A
Apr 27, 2021	invesco ltd.	8.4%	8,698,775	SC 13D/A

Recent SEC filings of Evofem Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Mar 28, 2024	8-K	Current Report
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Evofem Biosciences Inc News

Latest updates

Evofem Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-25.5%	3,603,000	4,839,000	5,112,000	2,458,000	5,809,000	181,000	6,371,000	6,034,000	4,251,000	3,570,000	1,712,000	1,857,000	1,105,000	691,500	278,000
Costs and Expenses	-21.6%	6,447,000	8,219,000	8,664,000	9,794,000	9,388,000	12,233,000	25,095,000	30,453,000	33,180,000	40,988,000	45,081,000	42,999,000	45,977,000	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	45,081,000	42,999,000	45,977,000	36,019,500	26,434,000
S&GA Expenses	-10.8%	2,345,000	2,628,000	2,985,000	2,197,000	3,854,000	7,000,000	11,948,000	12,298,000	12,705,000	24,922,000	30,468,000	27,237,000	30,525,000	23,914,500	14,700,000
R&D Expenses	-57.0%	594,000	1,383,000	614,000	402,000	540,000	1,690,000	5,207,000	7,744,000	10,391,000	8,659,000	8,701,000	8,507,000	7,262,000	5,946,000	4,217,000
EBITDA Margin	8.9%	3.44	3.16	3.92	5.08	-2.38	-4.35	-5.76	-18.00	-16.47	-24.42	-30.04	-33.41	-68.89	-	-
Interest Expenses	144.6%	564,000	-1,263,500	2,400,000	2,400,000	565,000	362,000	800,000	700,000	523,000	313,000	700,000	700,000	1,152,000	1,700,000	700,000
Income Taxes	-	-	-	11,000	3,000	3,000	8,000	13,000	20,000	3,000	6,000	-	12,000	-1,000	2,000	2,000
Earnings Before Taxes	-127.5%	-4,809,000	-2,114,000	66,016,000	-8,555,000	-2,351,000	-8,328,000	89,519,000	-125,960,000	-31,885,000	-51,548,000	-74,061,000	-33,414,000	-46,152,000	-40,596,000	-29,897,000
EBT Margin	8.5%	3.16	2.91	3.45	4.74	-2.56	-4.55	-5.93	-18.21	-16.76	-24.89	-30.86	-34.54	-70.68	-	-
Net Income	-127.5%	-4,809,000	-2,114,000	66,005,000	-8,558,000	-2,354,000	-8,336,000	89,506,000	-125,980,000	-31,888,000	-51,554,000	-74,061,000	-33,426,000	-46,151,000	-40,598,000	-29,899,000
Net Income Margin	8.5%	3.16	2.91	3.45	4.74	-2.56	-4.56	-5.93	-18.21	-16.76	-24.89	-30.86	-34.54	-70.68	-	-
Free Cashflow	164.1%	109,000	-170,000	-2,364,000	-1,495,000	-4,943,000	-6,566,000	-16,370,000	-26,830,000	-20,985,000	-21,318,000	-37,964,000	-54,910,000	-35,414,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-22.1%	8.00	11.00	13.00	14.00	26.00	25.00	42.00	53.00	35.00	43.00	67.00	109	93.00	110	112	135	16.00	28.00	39.00	54.00	3.00
Current Assets	-24.8%	7.00	9.00	12.00	12.00	17.00	13.00	32.00	42.00	21.00	30.00	55.00	96.00	80.00	98.00	102	128	14.00	26.00	38.00	53.00	1.00
Cash Equivalents	18.8%	1.00	1.00	-	-	1.00	3.00	8.00	20.00	3.00	14.00	15.00	47.00	45.00	72.00	87.00	124	9.00	17.00	32.00	51.00	0.00
Inventory	-23.0%	1.00	2.00	3.00	4.00	5.00	5.00	-	-	-	8.00	10.00	11.00	9.00	7.00	3.00	1.00	-	-	-	-	-
Net PPE	-0.2%	1.00	1.00	2.00	2.00	4.00	4.00	4.00	5.00	6.00	6.00	6.00	6.00	6.00	4.00	2.00	1.00	1.00	0.00	1.00	0.00	1.00
Liabilities	2.4%	74.00	72.00	68.00	70.00	82.00	97.00	120	269	159	142	126	100	107	109	72.00	67.00	15.00	13.00	15.00	19.00	32.00
Current Liabilities	2.5%	74.00	72.00	68.00	70.00	80.00	94.00	117	266	154	138	95.00	68.00	76.00	77.00	66.00	62.00	14.00	13.00	15.00	19.00	32.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	27.00	26.00	26.00	25.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	27.00	26.00	26.00	25.00	-	-	-	-	-	-	-
Shareholder's Equity	-6.2%	-70.67	-66.51	-	-	-56.40	-71.80	-	-	-	-104	-	9.00	-	1.00	40.00	69.00	1.00	16.00	24.00	36.00	-
Retained Earnings	-0.6%	-893	-888	-884	-949	-941	-938	-930	-1,000	-892	-860	-809	-735	-701	-655	-614	-585	-532	-513	-500	-486	-451
Additional Paid-In Capital	0.0%	823	823	829	821	820	817	815	802	759	751	745	744	688	657	655	654	533	529	525	522	422
Shares Outstanding	129.6%	46.00	20.00	6.00	3.00	-	121	102	-	12.00	-	8.00	7.00	5.00	5.00	-	-	-	-	-	-	-
Float	-	-	-	-	2.00	-	-	-	89.00	-	-	-	173	-	-	-	191	-	-	-	43.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	172.4%	123	-170	-2,364	-1,494	-4,940	-6,531	-16,300	-26,660	-20,919	-21,265	-37,367	-53,577	-34,458	-39,079	-35,822	-15,052	-14,876	-13,446	-14,425	-19,548	-7,678
Share Based Compensation	-3.7%	237	246	258	268	417	183	982	1,081	1,067	1,350	1,091	2,993	3,464	1,625	1,637	6,034	3,401	1,839	2,263	2,515	1,962
Cashflow From Investing	-Infinity%	-14.00	-	-	-1.00	-3.00	-35.00	-70.00	-170	-66.00	-53.00	-597	-1,333	-706	-1,421	-297	1,045	6,902	-4,627	-3,738	-	250
Cashflow From Financing	-100.0%	-	340	2,138	597	1,701	1,500	3,946	41,364	15,129	9,866	16.00	52,805	28,006	24,917	-603	128,548	1,364	2,192	-411	70,028	6,267
Buy Backs	-	-	-	-	-	-	-	-	18.00	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EVFM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product sales, net	$ 3,603	$ 5,809
Operating Expenses:
Cost of goods sold	684	1,376
Research and development	594	540
Selling and marketing	2,345	3,854
General and administrative	2,824	3,618
Total operating expenses	6,447	9,388
Loss from operations	(2,844)	(3,579)
Other income (expense):
Interest income	4	18
Other expense, net	(616)	(318)
Loss on issuance of financial instruments (Note 8)	(3,275)	(84)
Gain on debt extinguishment	1,120
Change in fair value of financial instruments (Note 6)	802	1,612
Total other income (expense), net	(1,965)	1,228
Loss before income tax	(4,809)	(2,351)
Income tax expense		(3)
Net loss	(4,809)	(2,354)
Convertible preferred stock deemed dividends	(47)
Net loss attributable to common stockholders	$ (4,856)	$ (2,354)
Net loss per share attributable to common stockholders
Earnings per share - basic	$ (0.16)	$ (1.85)
Earnings per share - diluted	$ (0.16)	$ (1.85)
Weighted-average shares used to compute net
loss per share attributable to common shareholders - basic	31,194,393	1,271,524
loss per share attributable to common shareholders - diluted	31,194,393	1,271,524

EVFM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents
Restricted cash	689	580
Trade accounts receivable, net	4,306	5,738
Inventories	1,306	1,697
Prepaid and other current assets	622	1,195
Total current assets	6,923	9,210
Property and equipment, net	1,200	1,203
Operating lease right-of-use assets	59	106
Other noncurrent assets	35	35
Total assets	8,217	10,554
Current liabilities:
Accounts payable	16,294	17,020
Accrued expenses	4,575	4,227
Accrued compensation	3,261	2,609
Operating lease liabilities-current	55	97
Derivative liabilities	4,310	1,926
Other current liabilities	3,391	3,316
Total current liabilities	74,239	72,463
Operating lease liabilities- noncurrent	4	8
Total liabilities	74,243	72,471
Commitments and contingencies (Note 7)
Convertible and redeemable preferred stock, $0.0001 par value, Senior to common stock
Series E-1, and F-1 convertible preferred stock, 2,300 and 95,000 shares authorized; 1,921 and 1,874 shares of E-1 issued and outstanding at March 31, 2024 and December 31, 2023, respectively; 22,280 shares of F-1 issued and outstanding at each of March 31, 2024 and December 31, 2023	4,640	4,593
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 48,710,395 and 20,007,799 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	5	2
Additional paid-in capital	823,409	823,036
Accumulated other comprehensive loss	(525)	(849)
Accumulated deficit	(893,555)	(888,699)
Total stockholders’ deficit	(70,666)	(66,510)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit	8,217	10,554
Baker Bros. Notes [Member]
Current liabilities:
Convertible notes	13,252	14,731
Adjuvant Notes [Member]
Current liabilities:
Convertible notes	$ 29,101	$ 28,537

About Evofem Biosciences Inc

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

CEO	Ms. Saundra Pelletier
WEBSITE	evofem.com
INDUSTRY	Biotechnology
EMPLOYEES	35

Evofem Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Evofem Biosciences Inc? What does EVFM stand for in stocks?

EVFM is the stock ticker symbol of Evofem Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Evofem Biosciences Inc (EVFM)?

As of Fri May 17 2024, market cap of Evofem Biosciences Inc is 620.6 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EVFM stock?

You can check EVFM's fair value in chart for subscribers.

What is the fair value of EVFM stock?

You can check EVFM's fair value in chart for subscribers. The fair value of Evofem Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Evofem Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EVFM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Evofem Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether EVFM is over valued or under valued. Whether Evofem Biosciences Inc is cheap or expensive depends on the assumptions which impact Evofem Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EVFM.

What is Evofem Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EVFM's PE ratio (Price to Earnings) is 0.01 and Price to Sales (PS) ratio is 0.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EVFM PE ratio will change depending on the future growth rate expectations of investors.